Citigroup Issues Positive Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price

Olema Pharmaceuticals (NASDAQ:OLMA) had its price objective boosted by Citigroup from $60.00 to $62.00 in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

OLMA has been the topic of a number of other reports. The Goldman Sachs Group upped their price target on Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Guggenheim lowered their price objective on Olema Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating for the company in a research report on Tuesday. TD Cowen restated a “buy” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Oppenheimer reiterated an “outperform” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Olema Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $43.22.

Olema Pharmaceuticals Stock Down 9.3%

NASDAQ:OLMA opened at $15.06 on Tuesday. The company’s 50-day simple moving average is $23.81 and its 200-day simple moving average is $18.73. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03. Olema Pharmaceuticals has a fifty-two week low of $2.86 and a fifty-two week high of $36.26. The stock has a market capitalization of $1.03 billion, a P/E ratio of -8.10 and a beta of 1.92.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings data on Monday, March 16th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.01. On average, equities analysts anticipate that Olema Pharmaceuticals will post -2.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider David C. Myles sold 51,000 shares of the company’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $30.46, for a total value of $1,553,460.00. Following the sale, the insider owned 551,881 shares in the company, valued at $16,810,295.26. This represents a 8.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Naseem Zojwalla sold 100,000 shares of the firm’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $28.04, for a total value of $2,804,000.00. Following the sale, the insider directly owned 53,997 shares in the company, valued at approximately $1,514,075.88. This trade represents a 64.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 805,501 shares of company stock worth $23,003,832. 16.36% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Olema Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC increased its holdings in shares of Olema Pharmaceuticals by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $94,000 after purchasing an additional 477 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Olema Pharmaceuticals by 8.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,018 shares of the company’s stock worth $325,000 after buying an additional 987 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Olema Pharmaceuticals by 44.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock valued at $96,000 after buying an additional 1,169 shares during the period. EverSource Wealth Advisors LLC increased its holdings in Olema Pharmaceuticals by 9,476.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after buying an additional 1,232 shares in the last quarter. Finally, ProShare Advisors LLC increased its holdings in Olema Pharmaceuticals by 13.8% in the fourth quarter. ProShare Advisors LLC now owns 14,367 shares of the company’s stock valued at $359,000 after buying an additional 1,740 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Olema Pharmaceuticals News Roundup

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Company update: Olema reiterated clinical progress and strong cash position — OPERA‑01 pivotal top‑line readout still on track for fall 2026, OPERA‑02 enrollment advanced, a Phase 1b/2 combo study with Pfizer’s atirmociclib was initiated, OP‑3136 enrollment continues with initial data expected in Q2 2026, and the company ended 2025 with $505.4M in cash after raising $218.5M in a follow‑on offering. These items materially de‑risk near‑term financing and support runway into late‑stage catalysts. Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
• Positive Sentiment: Earnings beat (small): Olema reported Q4 EPS of ($0.50), narrowly beating consensus of ($0.51). The modest beat appears to have supported a short‑term rally yesterday. View Press Release
• Positive Sentiment: Bullish analyst action: Citigroup raised its price target from $60 to $62 and maintained a Buy rating, implying substantial upside vs. current levels — a supportive read for longer‑term holders. Benzinga
• Neutral Sentiment: Analyst revision with mixed tone: Guggenheim trimmed its price target from $40 to $38 but kept a Buy rating, a mild pullback in expectations that still signals conviction in the thesis. Benzinga
• Negative Sentiment: Near‑term selling pressure: Shares fell today after a notable intraday jump yesterday (around a 9% move) following the earnings surprise — the pullback looks consistent with profit‑taking after the rally and the mixed analyst actions (Guggenheim’s lower PT). The combination of short‑term traders taking gains and differing analyst targets is likely weighing on the stock despite operational positives. Olema Pharmaceuticals (OLMA) Stock Jumps 9% Following Fourth Quarter Earnings Surprise

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.